Stockreport

Zenas BioPharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]

Zenas BioPharma, Inc.  (ZBIO) 
PDF Zenas BioPharma - Obexelimab marketing applications for the treatment of IgG4-RD expected to be submitted to the FDA in Q2 2026 and the EMA in H2 2026 based on the Ph [Read more]